Arix Bioscience plc
Change of Broker
LONDON, 07 November, 2019: Arix Bioscience plc (“Arixâ€, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it has appointed Peel Hunt LLP as joint corporate broker, with immediate effect, alongside its existing corporate broker Jefferies International Limited.
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
Optimum Strategic Communications
Mary Clark, Supriya Mathur
+44 (0)203 714 1787
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com